Principal Financial Group Inc Kymera Therapeutics, Inc. Transaction History

Principal Financial Group Inc

$162 Billion
Q1 2024

A detailed history of Principal Financial Group Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 12,098 shares of KYMR stock, worth $365,964. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,098

Previous 11,551 4.74%

Holding current value

$365,964

Previous $294,000 65.31%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$22.9 - $43.57 $12,526 - $23,832	547 Added 4.74%	12,098 $486,000
Q4 2023 Feb 07, 2024	SELL	$10.97 - $26.84 $351 - $858	-32 Reduced 0.28%	11,551 $294,000
Q3 2023 Nov 02, 2023	SELL	$13.9 - $23.88 $2,015 - $3,462	-145 Reduced 1.24%	11,583 $161,000
Q2 2023 Aug 07, 2023	SELL	$22.4 - $34.92 $14,582 - $22,732	-651 Reduced 5.26%	11,728 $269,000
Q1 2023 May 09, 2023	BUY	$24.84 - $38.75 $38,079 - $59,403	1,533 Added 14.13%	12,379 $366,000

Q4 2022 Feb 09, 2023	BUY	$19.57 - $30.92 $18,924 - $29,899	967 Added 9.79%	10,846 $270,000
Q3 2022 Nov 09, 2022	BUY	$20.91 - $34.27 $206,569 - $338,553	9,879 New	9,879 $215,000
Q2 2022 Aug 10, 2022	SELL	$14.13 - $42.55 $170,238 - $512,642	-12,048 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$35.3 - $64.68 $2,506 - $4,592	71 Added 0.59%	12,048 $510,000
Q4 2021 Feb 09, 2022	BUY	$49.91 - $65.56 $237,920 - $312,524	4,767 Added 66.12%	11,977 $760,000
Q3 2021 Nov 09, 2021	BUY	$47.8 - $66.66 $123,754 - $172,582	2,589 Added 56.03%	7,210 $424,000
Q2 2021 Aug 10, 2021	BUY	$31.08 - $51.95 $143,620 - $240,060	4,621 New	4,621 $224,000

Others Institutions Holding KYMR

# of Institutions

164

Shares Held

63.1M

Call Options Held

39.7K

Put Options Held

9.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $1.65B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Kymera Therapeutics, Inc. Transaction History